Emerging and re-emerging infectious
diseases due to RNA viruses
cause major negative consequences for the quality of life, public
health, and overall economic development. Most of the RNA viruses
causing illnesses in humans are of zoonotic origin. Zoonotic viruses
can directly be transferred from animals to humans through adaptation,
followed by human-to-human transmission, such as in human immunodeficiency
virus (HIV), severe acute respiratory syndrome coronavirus (SARS-CoV),
Middle East respiratory syndrome coronavirus (MERS-CoV), and, more
recently, SARS coronavirus 2 (SARS-CoV-2), or they can be transferred
through insects or vectors, as in the case of Crimean-Congo hemorrhagic
fever virus (CCHFV), Zika virus (ZIKV), and dengue virus (DENV). At
the present, there are no vaccines or antiviral compounds against
most of these viruses. Because proteins possess a vast array of functions
in all known biological systems, proteomics-based strategies can provide
important insights into the investigation of disease pathogenesis
and the identification of promising antiviral drug targets during
an epidemic or pandemic. Mass spectrometry technology has provided
the capacity required for the precise identification and the sensitive
and high-throughput analysis of proteins on a large scale and has
contributed greatly to unravelling key protein–protein interactions,
discovering signaling networks, and understanding disease mechanisms.
In this Review, we present an account of quantitative proteomics and
its application in some prominent recent examples of emerging and
re-emerging RNA virus diseases like HIV-1, CCHFV, ZIKV, and DENV,
with more detail with respect to coronaviruses (MERS-CoV and SARS-CoV)
as well as the recent SARS-CoV-2 pandemic.